Novo Digs In to Protect Its No. 1 Spot in Obesity Pill Market

Earlier this year, Novo Nordisk A/S pulled off the best obesity-drug launch ever with its Wegovy pill. Now it’s focused on building on more than 600,000 prescriptions as Eli Lilly & Co. threatens to siphon patients away with a new pill of its own.

“We’re focused on use, users and usage,” said Jamey Millar, the Danish drugmaker’s executive vice president of US operations, in an interview Wednesday.